Drugs / INCA33890
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05836324 | Jul 2023 → Jan 2027 expected | cancer, metastatic neoplasm | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07823322 | Oct 2026 → May 2029 expected | colorectal cancer | Incyte Corporation | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07284849 | Mar 2026 → Dec 2028 expected | colorectal cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06179160 Background | Jan 2024 → Jan 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-19 | Incyte Corporation | Results Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma incyte.com ↗
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer |
| 2025-04-25 | Incyte Corporation | Results Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 incyte.com ↗
INCA33890, a Bispecific Antibody Targeting PD-1 and TGFβR2, Shows Enhanced Immune Responses in Models of Ovarian Cancer |
All press releases naming this drug 3 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCA33890 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284849 ↗ |